APPILI THERAPEUTICS

In The Global Race 
Against Infectious Diseases

Internal Innovation; Active In-Licensing.

Appili Therapeutics is proud to be at the forefront of global efforts to address serious infectious disease threats.

Our systematic approach to building a diverse pipeline provides investment opportunities that serve the needs of patients, payers, and clinicians. Our strategy centers on identifying unmet medical needs, rather than adhering to a specific platform or technology, and matching those needs with potential solutions in the marketplace. This approach provides financial stability and the opportunity to leverage a broad range of government and industry programs, as well as to develop transformative programs that can impact the fundamental treatment landscape for many types of infections.

Latest News

INVESTOR QUICK LINKS

VIDEO: Appili Therapeutics is well funded and working to combat infectious diseases

May 18, 2022
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
May 17, 2022
Appili Therapeutics Announces Overnight Marketed Equity Offering
April 27, 2022
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2022
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis